APS.TO - Aptose Biosciences Inc.

Toronto - Toronto Delayed Price. Currency in CAD

Aptose Biosciences Inc.

251 Consumers Road
Suite 1105
Toronto, ON M2J 4R3

Full Time Employees22

Key Executives

NameTitlePayExercisedYear Born
Dr. William G. RiceChairman, Pres & CEO833.02kN/A1959
Mr. Gregory K. ChowExec. VP, Corp. Sec. & CFO534.58kN/A1973
Dr. Daniel Douglas Von Hoff FACP, M.D., F.A.C.P.Sr. VP of Medical Affairs, Special Advisor & Member of Scientific Advisory BoardN/AN/A1948
Dr. Stephen B. HowellChief Medical OfficerN/AN/A1945
Dr. Jotin Marango Ph.D., M.D.Sr. VP & Chief Bus. OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase I clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.

Corporate Governance

Aptose Biosciences Inc.’s ISS Governance QualityScore as of October 4, 2019 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.